Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | MST1R | Q04912 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17057025 | 0.81 | DPP4 (0.41) | DPP4ERN1ALDH1A1MAPTMEN1 | |
| SCHEMBL9696347 | 0.80 | PRKDC (0.41) | DPP4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9414143 | 0.76 | DPP4 (0.42) | DPP4ERN1KDM4EALDH1A1MAPT | |
| SCHEMBL10551507 | 0.74 | ERN1 (0.44) | DPP4ERN1KDM4EALDH1A1MAPT | |
| SCHEMBL31231819 | 0.73 | ERN1 (0.54) | DPP4ERN1KDM4EALDH1A1MAPT | |
| SCHEMBL2461016 | 0.73 | BCAT2 (0.47) | ALDH1A1MAPTHPGDHSD17B10MEN1 | |
| SCHEMBL19156075 | 0.73 | DPP4 (0.44) | DPP4ERN1KDM4EALDH1A1MAPT | |
| SCHEMBL1891145 | 0.72 | ERN1 (0.49) | DPP4ERN1ALDH1A1TSHRLTK | |
| SCHEMBL31456556 | 0.72 | ERN1 (0.49) | DPP4ERN1ALDH1A1TSHRLTK | |
| Hydrochloric Acid SCHEMBL20212707 | 0.71 | ERN1 (0.47) | DPP4ERN1ALDH1A1TSHRLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392687-B1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20110193072-A1 | FULLERENE DERIVATIVE, COMPOSITION, AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2345651-A1 | FULLERENE DERIVATIVE, COMPOSITION, AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20060178390-A1 | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JORDAN ALFONZO | 2006-08-10 | — | — | US | disclosed |
| US-7053101-B2 | 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JORDAN ALFONZO | 2006-05-30 | — | — | US | disclosed |
| US-20050004154-A1 | 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JORDAN ALFONZO (US) | 2005-01-06 | — | — | US | disclosed |
| US-6777421-B2 | TREATING A CONDITION SELECTED FROM THE GROUP CONSISTING OF ANXIETY, DEPRESSION, SUBSTANCE ABUSE, NEUROPATHIC PAIN, ACUTE PAIN, MIGRAINE, ASTHMA, COUGH AND IMPROVED COGNITION, IN A SUBJECT IN NEED THEREOF COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1392687-A1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | disclosed |
| WO-2002083673-A1 | 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2000032598-A9 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000032598-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY | STRUCTURAL BIOINFORMATICS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0588785-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0585999-A1 | Functional heteroaromatics for NLO applications | ENICHEM S.p.A. (IT) | 1994-03-09 | — | — | EP | disclosed |
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0588785-A4 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1991-12-30 | — | — | EP | disclosed |
| WO-1990012008-A1 | UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004154-A1 | 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | OPRL1, CALCRL, OPRK1 | DPP4 1268/4885ERN1 2989/4885KDM4E 4442/4885 |
| US-20060178390-A1 | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, OPRK1, CALCRL | DPP4 1536/4885ERN1 2318/4885KDM4E 4550/4885 |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, GPR4, GPR174 | DPP4 1000/4885ERN1 2390/4885KDM4E 4355/4885 |
| US-20110193072-A1 | FULLERENE DERIVATIVE, COMPOSITION, AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT | C1S, CYP2S1, CCNE2 | DPP4 4556/4885ERN1 1474/4885KDM4E 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.